Optimizing the Clinical Use of the GLP-1 Receptor Agonist Exenatide Once Weekly
نویسندگان
چکیده
منابع مشابه
The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes
OBJECTIVE Taspoglutide is a long-acting glucagon-like peptide 1 receptor agonist developed for treatment of type 2 diabetes. The efficacy and safety of once-weekly taspoglutide was compared with twice-daily exenatide. RESEARCH DESIGN AND METHODS Overweight adults with inadequately controlled type 2 diabetes on metformin ± a thiazolidinedione were randomized to subcutaneous taspoglutide 10 mg ...
متن کاملExenatide once weekly: clinical outcomes and patient satisfaction
BACKGROUND Type 2 diabetes mellitus (T2DM) is a complex disorder in which interactions between environmental and genetic factors result in the development of insulin resistance (in most cases) and progressive pancreatic β-cell failure. The currently available oral anti-diabetes treatments are effective as monotherapy; however, due to the progressive decline in β-cell function, most patients wil...
متن کاملExenatide Once Weekly for Smoking Cessation: A Randomized Clinical Trial
Background: Cigarette smoking is the greatest preventable cause of morbidity and premature mortality in the US. Approved pharmacological treatments for smoking cessation are only marginally effective, underscoring the need for improved pharmacotherapies. Glucagon-like peptide-1 (GLP-1) is produced in the intestinal L-cells and in the hindbrain nucleus solitarius. GLP-1 functions to maintain glu...
متن کاملGLP-1 receptor agonists: why is once weekly inferior to once daily?
In The Lancet Diabetes & Endocrinology, Richard Pratley and colleagues report the results of a phase 3 registration trial of albiglutide, a new once-weekly glucagonlike peptide-1 (GLP-1) receptor agonist. Albiglutide is a unique chemical entity with a high molecular weight, composed of two GLP-1 molecules fused to an albumin molecule, and has a half-life of 5 days. In their noninferiority trial...
متن کاملSIRT1 mediates the effect of GLP-1 receptor agonist exenatide on ameliorating hepatic steatosis.
GLP-1 and incretin mimetics, such as exenatide, have been shown to attenuate hepatocyte steatosis in vivo and in vitro, but the specific underlying mechanism is unclear. SIRT1, an NAD(+)-dependent protein deacetylase, has been considered as a crucial regulator in hepatic lipid homeostasis by accumulated studies. Here, we speculate that SIRT1 might mediate the effect of the GLP-1 receptor agonis...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Diabetes Spectrum
سال: 2013
ISSN: 1040-9165,1944-7353
DOI: 10.2337/diaspect.26.1.46